Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia

References

• Collins PY, Patel V, Joestl SS, et al. Grand challenges in global mental health. Nature 2011;475:27-30
   PubMed Web of Science ®Google Scholar
• Gustavsson A, Svensson M, Jacobi F, et al. Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718-79
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO. http://www.who.int/mental_health/management/schizophrenia/en. Accessed 2012
   Google Scholar
• Offord S, Lin J, Mirski D, et al. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther 2013;30:286-97
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, et al. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176:109-13
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatric Serv 2004;55:886-91
   PubMed Web of Science ®Google Scholar
• Weiden P, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29
   PubMed Web of Science ®Google Scholar
• Marcus S, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008;34:173-80
   PubMed Web of Science ®Google Scholar
• Keith S. Advances in psychotropic formulations. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:996-1008
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Res 2011;127:83-92
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011;168:603-9
   PubMed Web of Science ®Google Scholar
• De Berardis D, Marini S, Carano A, et al. Efficacy and safety of long acting injectable atypical antipsychotics: a review. Current Clin Pharmacol 2013:[Epub ahead of print]
   Google Scholar
• FDA. Drugs@FDA. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
   Google Scholar
• Kane J, Sanchez R, Perry P, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617-24
   PubMed Web of Science ®Google Scholar
• Otsuka America Pharmaceuticals Inc. Abilify Maintena Prescribing Information. 2013. http://www.otsuka-us.com/Products/Documents/Abilify.M.PI.pdf
   Google Scholar
• Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77
   PubMed Web of Science ®Google Scholar
• Bera R, Offord S, Zubek D, et al. Impact on healthcare resource usage and costs among Medicaid-insured schizophrenia patients after initiation of treatment with long-acting injectable antipsychotics. J Med Econ 2013;16:522-8
   PubMedGoogle Scholar
• Lin J, Wong B, Offord S, et al. Healthcare cost reductions associated with the use of lai formulations of antipsychotic medications versus oral among patients with schizophrenia. J Behav Health Serv Rers 2013. [Epub ahead of print]
   Google Scholar
• De Graeve D, Smet A, Mehnert A, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. Pharmacoeconomics 2005;23(1 Suppl):35-47
   PubMedGoogle Scholar
• Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(1 Suppl):75-89
   PubMedGoogle Scholar
• Olivares JM, Rodriguez-Martinez A, Buron JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008;6:41-53
   PubMedGoogle Scholar
• Haddad P, Taylor M, Niaz OS. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies. Br J Psychiatry 2009;52:S20-8
   Google Scholar
• Asseburg C, Willis M, Lothgren M, et al. Hospitalisation utilisation and costs in schizophrenia patients in finland before and after initiation of risperidone long-acting injection. Schizophr Res Treat 2012;2012:791468 . doi: 10.1155/2012/791468
   PubMedGoogle Scholar
• Carswell C, Wheeler A, Vanderpyl J, et al. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin Drug Investig 2010;30:777-87
   PubMed Web of Science ®Google Scholar
• Spill B, Konoppa S, Kissling W, et al. Long-term observation of patients successfully switched to risperidone long-acting injectable: a retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs. Int J Psychiatry Clin Pract 2010;14:53-62
   PubMed Web of Science ®Google Scholar
• Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ 2009;12:317-24
   PubMedGoogle Scholar
• Peng X, Ascher-Svanum H, Faries D, et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res 2011;3:9-14
   PubMedGoogle Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull [Epub ahead of print]
   Google Scholar
• Fleischhacker WW, Sanchez R, Perry PP, et al. Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind, randomized, non-inferiority study vs. oral aripiprazole. 51st Annual Meeting of the American College of Neuropsychopharmacology (ACNP); 2-6 December 2012; Hollywood, FL
   Google Scholar
• Essock S, Covell N, Davis S, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006;163:2090-5
   PubMed Web of Science ®Google Scholar